Phase 1b exploratory study of [18F]AH111585-PET as a marker of angiogenic response to combination therapy with the pan-VEGF inhibitor, pazopanib, and weekly paclitaxel in platinum resistant ovarian cancer.

Trial Profile

Phase 1b exploratory study of [18F]AH111585-PET as a marker of angiogenic response to combination therapy with the pan-VEGF inhibitor, pazopanib, and weekly paclitaxel in platinum resistant ovarian cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Mar 2017

At a glance

  • Drugs Pazopanib (Primary) ; Paclitaxel
  • Indications Ovarian cancer
  • Focus Therapeutic Use
  • Acronyms PAZ-PET; PAZPET-1
  • Most Recent Events

    • 09 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 16 Feb 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
    • 09 Feb 2016 Accrual to date is 107% according to United Kingdom Clinical Research Network
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top